Cholesterol

Identification

Name
Cholesterol
Accession Number
DB04540  (EXPT00945)
Type
Small Molecule
Groups
Experimental
Description

The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. [PubChem]

Structure
Thumb
Synonyms
Not Available
External IDs
NSC-8798
Product Ingredients
IngredientUNIICASInChI Key
Cholesteryl chloride39EHZ05V39 910-31-6OTVRYZXVVMZHHW-DPAQBDIFSA-N
Cholesteryl sulfateNot Available1256-86-6BHYOQNUELFTYRT-DPAQBDIFSA-N
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
97C5T2UQ7J
CAS number
57-88-5
Weight
Average: 386.6535
Monoisotopic: 386.354866094
Chemical Formula
C27H46O
InChI Key
HVYWMOMLDIMFJA-DPAQBDIFSA-N
InChI
InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1
IUPAC Name
(1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-5-ol
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UNuclear receptor ROR-alphaNot AvailableHuman
UNuclear receptor subfamily 1 group I member 3Not AvailableHuman
UVitamin D3 receptorNot AvailableHuman
UC-type lectin domain family 4 member E
ligand
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Rosuvastatin Action PathwayDrug action
Fluvastatin Action PathwayDrug action
CHILD SyndromeDisease
Hyper-IgD syndromeDisease
Corticosterone methyl oxidase I deficiency (CMO I)Disease
27-Hydroxylase DeficiencyDisease
Cerivastatin Action PathwayDrug action
Pamidronate Action PathwayDrug action
SteroidogenesisMetabolic
Atorvastatin Action PathwayDrug action
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase DeficiencyDisease
Cholesteryl ester storage diseaseDisease
Mevalonic aciduriaDisease
Alendronate Action PathwayDrug action
Zoledronate Action PathwayDrug action
Cerebrotendinous Xanthomatosis (CTX)Disease
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDisease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase DeficiencyDisease
Wolman diseaseDisease
11-beta-hydroxylase deficiency (CYP11B1)Disease
Corticosterone methyl oxidase II deficiency - CMO IIDisease
Pravastatin Action PathwayDrug action
Risedronate Action PathwayDrug action
HypercholesterolemiaDisease
Congenital Bile Acid Synthesis Defect Type IIDisease
Zellweger SyndromeDisease
Congenital Bile Acid Synthesis Defect Type IIIDisease
21-hydroxylase deficiency (CYP21)Disease
Apparent mineralocorticoid excess syndromeDisease
3-Beta-Hydroxysteroid Dehydrogenase DeficiencyDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cholesterol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Cholesterol.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cholesterol.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cholesterol.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Cholesterol.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Cholesterol.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cholesterol.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cholesterol.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cholesterol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Cholesterol.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Cholesterol.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Cholesterol.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Cholesterol.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cholesterol.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cholesterol.Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cholesterol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cholesterol.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Cholesterol.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Cholesterol.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Cholesterol.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Cholesterol.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cholesterol.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cholesterol.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Cholesterol.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Cholesterol.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cholesterol.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Cholesterol.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Cholesterol.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Cholesterol.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Cholesterol.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Cholesterol.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Cholesterol.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cholesterol.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cholesterol.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Cholesterol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Cholesterol.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cholesterol.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cholesterol.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cholesterol.Approved
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cholesterol.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Cholesterol.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cholesterol.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Cholesterol.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Cholesterol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cholesterol.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Cholesterol.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Cholesterol.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cholesterol.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Cholesterol.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cholesterol.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Cholesterol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Cholesterol.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cholesterol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cholesterol.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cholesterol.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Cholesterol.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Cholesterol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cholesterol.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cholesterol.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cholesterol.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cholesterol.Approved, Investigational
EltrombopagThe serum concentration of Cholesterol can be increased when it is combined with Eltrombopag.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cholesterol.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Cholesterol.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Cholesterol.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cholesterol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Cholesterol.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Cholesterol.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cholesterol.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Cholesterol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cholesterol.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cholesterol.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cholesterol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Cholesterol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cholesterol.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cholesterol.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Cholesterol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Cholesterol.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cholesterol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Cholesterol.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Cholesterol.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Cholesterol.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cholesterol.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Cholesterol.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Cholesterol.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cholesterol.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cholesterol.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Cholesterol.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Cholesterol.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Cholesterol.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Cholesterol.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cholesterol.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Cholesterol.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cholesterol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cholesterol.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Cholesterol.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cholesterol.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Cholesterol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Cholesterol.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cholesterol.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Cholesterol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cholesterol.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cholesterol.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Cholesterol.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Cholesterol.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Cholesterol.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cholesterol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cholesterol.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cholesterol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cholesterol.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cholesterol.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cholesterol.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Cholesterol.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cholesterol.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Cholesterol.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cholesterol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cholesterol.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Cholesterol.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cholesterol.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cholesterol.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Cholesterol.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cholesterol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cholesterol.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cholesterol.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cholesterol.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Cholesterol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Cholesterol.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Cholesterol.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cholesterol.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Cholesterol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cholesterol.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cholesterol.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Cholesterol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Cholesterol.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cholesterol.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Cholesterol.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Cholesterol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Cholesterol.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Cholesterol.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Cholesterol.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cholesterol.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Cholesterol.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cholesterol.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Cholesterol.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Cholesterol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cholesterol.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Cholesterol.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cholesterol.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cholesterol.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Cholesterol.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Cholesterol.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cholesterol.Approved
RolapitantThe serum concentration of Cholesterol can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Cholesterol.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cholesterol.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cholesterol.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cholesterol.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cholesterol.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Cholesterol.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cholesterol.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cholesterol.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Cholesterol.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Cholesterol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cholesterol.Experimental
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Cholesterol.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Cholesterol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Cholesterol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cholesterol.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Cholesterol.Withdrawn
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Cholesterol.Approved
TeriflunomideThe serum concentration of Cholesterol can be increased when it is combined with Teriflunomide.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cholesterol.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Cholesterol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cholesterol.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cholesterol.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Cholesterol.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Cholesterol.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cholesterol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cholesterol.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cholesterol.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Cholesterol.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Cholesterol.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cholesterol.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Cholesterol.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cholesterol.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Cholesterol.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Cholesterol.Approved
Food Interactions
Not Available

References

Synthesis Reference

Tatu Miettenen, Ingmar Wester, Hannu Vanhanen, "Substance for lowering high cholesterol level in serum and methods for preparing and using the same." U.S. Patent US6174560, issued February, 1944.

US6174560
General References
Not Available
External Links
KEGG Drug
D00040
KEGG Compound
C00187
ChemSpider
5775
BindingDB
20192
ChEBI
16113
ChEMBL
CHEMBL112570
HET
CLR
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionCardiovascular Disease (CVD) / Carotid Atherosclerosis / Diabetes / Hyperlipidemias / Hypertensive1
Not AvailableRecruitingTreatmentCone-Rod Dystrophy / Hard of Hearing / Smith-Lemli-Opitz Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)148.5 °CPhysProp
boiling point (°C)360 °CPhysProp
water solubility0.095 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
Predicted Properties
PropertyValueSource
Water Solubility2.79e-05 mg/mLALOGPS
logP7.02ALOGPS
logP7.11ChemAxon
logS-7.1ALOGPS
pKa (Strongest Acidic)18.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area20.23 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity120.62 m3·mol-1ChemAxon
Polarizability50.6 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9749
Caco-2 permeable+0.8184
P-glycoprotein substrateSubstrate0.6477
P-glycoprotein inhibitor IInhibitor0.6404
P-glycoprotein inhibitor IINon-inhibitor0.529
Renal organic cation transporterNon-inhibitor0.7691
CYP450 2C9 substrateNon-substrate0.8257
CYP450 2D6 substrateNon-substrate0.8794
CYP450 3A4 substrateSubstrate0.7439
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.9194
CYP450 2D6 inhibitorNon-inhibitor0.9519
CYP450 2C19 inhibitorNon-inhibitor0.9177
CYP450 3A4 inhibitorNon-inhibitor0.8638
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6721
Ames testNon AMES toxic0.8888
CarcinogenicityNon-carcinogens0.932
BiodegradationNot ready biodegradable0.9825
Rat acute toxicity2.8078 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.773
hERG inhibition (predictor II)Non-inhibitor0.7552
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-004i-3911000000-52f5261007adc218f8f8
GC-MS Spectrum - EI-BGC-MSsplash10-052b-2932000000-1667c83d002043a59fff
GC-MS Spectrum - EI-BGC-MSsplash10-000l-9527000000-5529a262047f5369c9c1
GC-MS Spectrum - EI-BGC-MSsplash10-0mkr-2954000000-60e7d1f5973e4de33dec
GC-MS Spectrum - CI-BGC-MSsplash10-014i-1009000000-e82b8e23dedb45ce70e6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-056v-2900000000-04687c9f19ff52ba4654
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4l-7922000000-36e8a5e1a77d2e71d1d1
1H NMR Spectrum1D NMRNot applicable
13C NMR Spectrum1D NMRNot applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as cholesterols and derivatives. These are compounds containing a 3-hydroxylated cholestane core.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Cholestane steroids
Direct Parent
Cholesterols and derivatives
Alternative Parents
3-beta-hydroxysteroids / 3-beta-hydroxy delta-5-steroids / Delta-5-steroids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
Substituents
Cholesterol-skeleton / Cholesterol / 3-beta-hydroxysteroid / 3-beta-hydroxy-delta-5-steroid / Hydroxysteroid / 3-hydroxysteroid / 3-hydroxy-delta-5-steroid / Delta-5-steroid / Cyclic alcohol / Secondary alcohol
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
cholestanoid, 3beta-sterol (CHEBI:16113 ) / cholestane, Cholesterol and derivatives, Cholestane and derivatives (C00187 ) / Cholesterol and derivatives (LMST01010001 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic ...
Gene Name
RORA
Uniprot ID
P35398
Uniprot Name
Nuclear receptor ROR-alpha
Molecular Weight
58974.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name
NR1I3
Uniprot ID
Q14994
Uniprot Name
Nuclear receptor subfamily 1 group I member 3
Molecular Weight
39942.145 Da
References
  1. Mooijaart SP, Brandt BW, Baldal EA, Pijpe J, Kuningas M, Beekman M, Zwaan BJ, Slagboom PE, Westendorp RG, van Heemst D: C. elegans DAF-12, Nuclear Hormone Receptors and human longevity and disease at old age. Ageing Res Rev. 2005 Aug;4(3):351-71. [PubMed:16051528 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
VDR
Uniprot ID
P11473
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
References
  1. Mooijaart SP, Brandt BW, Baldal EA, Pijpe J, Kuningas M, Beekman M, Zwaan BJ, Slagboom PE, Westendorp RG, van Heemst D: C. elegans DAF-12, Nuclear Hormone Receptors and human longevity and disease at old age. Ageing Res Rev. 2005 Aug;4(3):351-71. [PubMed:16051528 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Ligand
General Function
C-type lectin that functions as cell-surface receptor for a wide variety of ligands such as damaged cells, fungi and mycobacteria. Plays a role in the recognition of pathogenic fungi, such as Candida albicans. The detection of mycobacteria is via trehalose 6,6'-dimycolate (TDM), a cell wall glycolipid. Specifically recognizes alpha-mannose residues on pathogenic fungi of the genus Malassezia. Recognizes also SAP130, a nuclear protein, that is released by dead or dying cells. Transduces signals through an ITAM-containing adapter protein, Fc receptor gamma chain /FCER1G. Induces secretion of inflammatory cytokines through a pathway that depends on SYK, CARD9 and NF-kappa-B.
Specific Function
Carbohydrate binding
Gene Name
CLEC4E
Uniprot ID
Q9ULY5
Uniprot Name
C-type lectin domain family 4 member E
Molecular Weight
25072.31 Da
References
  1. Kiyotake R, Oh-Hora M, Ishikawa E, Miyamoto T, Ishibashi T, Yamasaki S: Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses. J Biol Chem. 2015 Oct 16;290(42):25322-32. doi: 10.1074/jbc.M115.645234. Epub 2015 Aug 20. [PubMed:26296894 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang E, Casciano CN, Clement RP, Johnson WW: Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16. [PubMed:11027568 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW: Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. Epub 2003 Mar 28. [PubMed:12668685 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 11:18